Argenx Se ADR (ARGX)

$1,002.31 -4.76 (-0.47%)
Market Cap 63.00B
Revenue (ttm) 4.25B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 39.68
Forward PE 35.47
Profit Margin 30.41%
Debt to Equity Ratio 0.00
Volume 209,900
Avg Vol 291,894
Day's Range N/A - N/A
Shares Out 62.56M
Stochastic %K 16%
Beta 0.47
Analysts Strong Sell
Price Target $1,193.52

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, gr...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 10 703 8441
Website: argenx.com
Address:
Laarderhoogtweg 25, Amsterdam, Netherlands
howardlindzon
howardlindzon Sep. 2 at 6:32 PM
$ARGX yet another biotech at all time highs
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Sep. 2 at 6:31 PM
$ARGX printed a new 52-week high today
0 · Reply
moneybag888
moneybag888 Sep. 2 at 4:57 PM
$REGN new 52w HIGH $ARGX
0 · Reply
tradehulk
tradehulk Aug. 28 at 1:30 PM
$ARGX $LITE ⚡ BREAKING: Core AI Holdings delivers a stellar Q2 with revenue up 56%! 📊💰
0 · Reply
moneybag888
moneybag888 Aug. 27 at 11:11 PM
$ARGX 3 gaps down? or $1200+ to $1400+ #believe #befirst #alwayshedge
1 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 27 at 4:01 PM
$ARGX printed a new 52-week high today
0 · Reply
doubleyou2
doubleyou2 Aug. 27 at 1:49 PM
$ARGX Done.
0 · Reply
CDMO
CDMO Aug. 26 at 7:01 PM
$ARGX such a beast
1 · Reply
mv21970
mv21970 Aug. 26 at 5:01 PM
$BHVN cash runway extended through 2028 with first pivotal data for their degrader plattform expected late 2027 .. to get an idea what the company might be worth if BHV-1300 succeeds, look no further than where $ARGX is trading
1 · Reply
briefingcom
briefingcom Aug. 26 at 12:25 PM
$ARGX: argenx (+2.8%) upgraded to Buy from Neutral at UBS, tgt $1,400 https://www.briefing.com/calendars/updown?Filter=All&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
Latest News on ARGX
argenx SE Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 8, 2026, 9:30 AM EDT - 1 day ago

argenx SE Transcript: Wells Fargo 21st Annual Healthcare Conference

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

Sep 2, 2026, 8:00 AM EDT - 7 days ago

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

ARGX

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Wed, 02 Sep 2026 04:44:00 -0400 - 8 days ago

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

argenx to Present at Upcoming Investor Conferences

Sep 1, 2026, 1:00 AM EDT - 9 days ago

argenx to Present at Upcoming Investor Conferences

ARGX

ARGX Maintained by Morgan Stanley -- Price Target Raised to $1250

2026-08-31T16:04:08.000Z - 9 days ago

ARGX Maintained by Morgan Stanley -- Price Target Raised to $1250

Argenx price target raised to $1,250 from $1,230 at Morgan Stanley

2026-08-31T11:35:41.000Z - 9 days ago

Argenx price target raised to $1,250 from $1,230 at Morgan Stanley

VRTX

argenx Completes Acquisition of Forte Biosciences, Inc.

Aug 27, 2026, 8:50 AM EDT - 13 days ago

argenx Completes Acquisition of Forte Biosciences, Inc.

ARGX

ARGX Upgraded by UBS -- Price Target Raised to $1400

2026-08-26T17:35:51.000Z - 14 days ago

ARGX Upgraded by UBS -- Price Target Raised to $1400

ARGX Looks 29.0% Undervalued on GF Value™

2026-08-26T16:00:31.000Z - 14 days ago

ARGX Looks 29.0% Undervalued on GF Value™

ARGX Maintains Rating by Wells Fargo -- Price Target Raised to $1415

2026-08-26T14:31:46.000Z - 14 days ago

ARGX Maintains Rating by Wells Fargo -- Price Target Raised to $1415

Argenx price target raised to $1,415 from $1,350 at Wells Fargo

2026-08-26T10:50:36.000Z - 14 days ago

Argenx price target raised to $1,415 from $1,350 at Wells Fargo

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story

Wed, 26 Aug 2026 04:46:00 -0400 - 15 days ago

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story

Argenx upgraded to Buy from Neutral at UBS

2026-08-26T08:45:22.000Z - 15 days ago

Argenx upgraded to Buy from Neutral at UBS

Argenx downgraded to Hold at Deutsche Bank after almost 50% advance

2026-08-24T14:15:18.000Z - 16 days ago

Argenx downgraded to Hold at Deutsche Bank after almost 50% advance

Argenx downgraded to Hold from Buy at Deutsche Bank

2026-08-24T14:10:10.000Z - 16 days ago

Argenx downgraded to Hold from Buy at Deutsche Bank

Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT

2026-08-24T10:34:50.000Z - 16 days ago

Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT

ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities

2026-08-18T18:30:23.000Z - 22 days ago

ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities

ARGX Maintained by RBC Capital -- Price Target Raised to $1100

2026-08-18T14:31:18.000Z - 22 days ago

ARGX Maintained by RBC Capital -- Price Target Raised to $1100

ARGX Maintained by Citizens -- Price Target Raised to $1200

2026-08-18T13:35:15.000Z - 22 days ago

ARGX Maintained by Citizens -- Price Target Raised to $1200

ARGX Maintains by Wedbush -- Price Target Raised to $1150

2026-08-18T13:34:53.000Z - 22 days ago

ARGX Maintains by Wedbush -- Price Target Raised to $1150

ARGX Maintained by HC Wainwright & Co. -- Price Target Raised to $1202

2026-08-18T13:30:30.000Z - 22 days ago

ARGX Maintained by HC Wainwright & Co. -- Price Target Raised to $1202

Argenx price target raised to $1,230 from $1,200 at Morgan Stanley

2026-08-18T12:26:46.000Z - 22 days ago

Argenx price target raised to $1,230 from $1,200 at Morgan Stanley

Argenx price target raised to $1,100 from $1,025 at RBC Capital

2026-08-18T12:15:09.000Z - 22 days ago

Argenx price target raised to $1,100 from $1,025 at RBC Capital

Argenx price target raised to $1,150 from $1,050 at Wedbush

2026-08-18T11:50:09.000Z - 22 days ago

Argenx price target raised to $1,150 from $1,050 at Wedbush

Argenx price target raised to $1,100 from $1,037 at Oppenheimer

2026-08-18T11:45:14.000Z - 22 days ago

Argenx price target raised to $1,100 from $1,037 at Oppenheimer

Argenx price target raised to $1,095 from $1,030 at Truist

2026-08-18T11:25:33.000Z - 22 days ago

Argenx price target raised to $1,095 from $1,030 at Truist

Argenx price target raised to $1,202 from $940 at H.C. Wainwright

2026-08-18T10:10:36.000Z - 22 days ago

Argenx price target raised to $1,202 from $940 at H.C. Wainwright

Argenx price target raised to $1,200 from $932 at Citizens

2026-08-18T09:45:28.000Z - 22 days ago

Argenx price target raised to $1,200 from $932 at Citizens

Argenx price target raised to $1,136 from $1,088 at BofA

2026-08-18T09:30:15.000Z - 22 days ago

Argenx price target raised to $1,136 from $1,088 at BofA

ARGX Looks 31.4% Undervalued on GF Value™ After Positive Vyvgart Trial Data

2026-08-17T19:50:36.000Z - 23 days ago

ARGX Looks 31.4% Undervalued on GF Value™ After Positive Vyvgart Trial Data

argenx SE Business Update Transcript

2026-08-17T19:00:18.000Z - 23 days ago

argenx SE Business Update Transcript

William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path

2026-08-17T18:20:27.000Z - 23 days ago

William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path

ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler

2026-08-17T17:33:31.000Z - 23 days ago

ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler

ARGX Looks 31.4% Undervalued on GF Value™ as Stock Surges 16.6%

2026-08-17T17:27:24.000Z - 23 days ago

ARGX Looks 31.4% Undervalued on GF Value™ as Stock Surges 16.6%

Argenx rises 16.6%

2026-08-17T16:05:31.000Z - 23 days ago

Argenx rises 16.6%

ARGX Looks 32.0% Undervalued on GF Value™

2026-08-17T15:31:17.000Z - 23 days ago

ARGX Looks 32.0% Undervalued on GF Value™

Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results

2026-08-17T14:11:11.000Z - 23 days ago

Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing

Mon, 17 Aug 2026 10:04:42 -0400 - 23 days ago

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing

Argenx rises 14.9%

2026-08-17T14:00:11.000Z - 23 days ago

Argenx rises 14.9%

Argenx's Vyvgart Scored Another Win — Why Shares Bolted Higher

2026-08-17T13:43:56.000Z - 23 days ago

Argenx's Vyvgart Scored Another Win — Why Shares Bolted Higher

argenx SE Transcript: Study update

Aug 17, 2026, 8:30 AM EDT - 23 days ago

argenx SE Transcript: Study update

argenx SE Press release: Study update

Aug 17, 2026, 8:30 AM EDT - 23 days ago

argenx SE Press release: Study update

argenx SE Slides: Study update

Aug 17, 2026, 8:30 AM EDT - 23 days ago

argenx SE Slides: Study update

ARGX Looks 41.1% Undervalued on GF Value™

2026-08-17T11:27:28.000Z - 23 days ago

ARGX Looks 41.1% Undervalued on GF Value™

Argenx price target raised to $1,215 from $1,075 at Piper Sandler

2026-08-17T11:06:52.000Z - 23 days ago

Argenx price target raised to $1,215 from $1,075 at Piper Sandler

ARGX Looks 41.1% Undervalued on GF Value™ as Phase 3 Trial Boosts Growth Prospects

2026-08-17T10:54:47.000Z - 23 days ago

ARGX Looks 41.1% Undervalued on GF Value™ as Phase 3 Trial Boosts Growth Prospects

Zai Lab and Argenx announce results from Alkivia Phase 3 study

2026-08-17T10:14:51.000Z - 23 days ago

Zai Lab and Argenx announce results from Alkivia Phase 3 study

ZLAB

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Aug 17, 2026, 6:00 AM EDT - 23 days ago

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

ARGX ZLAB

ARGX Looks 41.1% Undervalued on GF Value™ After Vyvgart Phase 3 Success

2026-08-17T09:55:34.000Z - 23 days ago

ARGX Looks 41.1% Undervalued on GF Value™ After Vyvgart Phase 3 Success

Argenx Reports Positive Phase 3 Results In Autoimmune Myositis; Stock Up

2026-08-17T07:46:13.000Z - 24 days ago

Argenx Reports Positive Phase 3 Results In Autoimmune Myositis; Stock Up

Argenx says efgartigimod met main goal in myositis trial

Aug 17, 2026, 1:27 AM EDT - 24 days ago

Argenx says efgartigimod met main goal in myositis trial

ARGX

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Aug 17, 2026, 1:00 AM EDT - 24 days ago

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

ARGX

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Tue, 11 Aug 2026 11:56:00 -0400 - 4 weeks ago

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

Aug 6, 2026, 7:48 AM EDT - 4 weeks ago

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

ARGX

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

Aug 3, 2026, 4:01 PM EDT - 5 weeks ago

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors

Jul 31, 2026, 3:16 AM EDT - 5 weeks ago

A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors

AZN CNQ NWG TECK

argenx SE Transcript: M&A announcement

Jul 27, 2026, 8:00 AM EDT - 6 weeks ago

argenx SE Transcript: M&A announcement

argenx SE Press release: M&A announcement

Jul 27, 2026, 8:00 AM EDT - 6 weeks ago

argenx SE Press release: M&A announcement

argenx SE Slides: M&A announcement

Jul 27, 2026, 8:00 AM EDT - 6 weeks ago

argenx SE Slides: M&A announcement

Argenx to Buy Forte Biosciences for $2.2 Billion

Jul 27, 2026, 1:29 AM EDT - 6 weeks ago

Argenx to Buy Forte Biosciences for $2.2 Billion

FBRX

Argenx to buy Forte Biosciences for about $2.2 billion

Jul 27, 2026, 1:15 AM EDT - 6 weeks ago

Argenx to buy Forte Biosciences for about $2.2 billion

FBRX

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Jul 27, 2026, 1:07 AM EDT - 6 weeks ago

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

FBRX

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

Jul 27, 2026, 1:00 AM EDT - 6 weeks ago

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

argenx SE Earnings Call Transcript: Q2 2026

Jul 23, 2026, 8:30 AM EDT - 6 weeks ago

argenx SE Earnings Call Transcript: Q2 2026

argenx SE Earnings release: Q2 2026

Jul 23, 2026, 8:30 AM EDT - 6 weeks ago

argenx SE Earnings release: Q2 2026

argenx SE Slides: Q2 2026

Jul 23, 2026, 8:30 AM EDT - 6 weeks ago

argenx SE Slides: Q2 2026

Argenx's Vyvgart sales jump in second quarter

Jul 23, 2026, 1:41 AM EDT - 7 weeks ago

Argenx's Vyvgart sales jump in second quarter

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Jul 16, 2026, 1:00 AM EDT - 1 month ago

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs

Jul 15, 2026, 8:09 AM EDT - 1 month ago

Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs

argenx SE Transcript: Status update

Jun 23, 2026, 2:00 PM EDT - 2 months ago

argenx SE Transcript: Status update

argenx SE Slides: Status update

Jun 23, 2026, 2:00 PM EDT - 2 months ago

argenx SE Slides: Status update

argenx SE Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 4:00 PM EDT - 3 months ago

argenx SE Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

argenx SE Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 1:40 PM EDT - 3 months ago

argenx SE Transcript: 46th Annual William Blair Growth Stock Conference

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

Jun 3, 2026, 1:00 AM EDT - 3 months ago

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026, 1:00 AM EDT - 3 months ago

argenx to Host Myositis R&D Webinar on June 23, 2026

argenx SE Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:40 PM EDT - 4 months ago

argenx SE Transcript: Bank of America Global Healthcare Conference 2026

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

May 8, 2026, 5:20 PM EDT - 4 months ago

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx SE Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

argenx SE Earnings Call Transcript: Q1 2026

argenx SE Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

argenx SE Earnings release: Q1 2026

argenx SE Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

argenx SE Slides: Q1 2026

argenx to Present at BofA Securities 2026 Health Care Conference

May 6, 2026, 4:30 PM EDT - 4 months ago

argenx to Present at BofA Securities 2026 Health Care Conference

argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer

May 6, 2026, 4:01 PM EDT - 4 months ago

argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

Apr 30, 2026, 1:00 AM EDT - 4 months ago

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

Apr 18, 2026, 1:00 AM EDT - 4 months ago

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency

Mar 24, 2026, 9:00 AM EDT - 5 months ago

eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Mar 6, 2026, 1:00 AM EST - 6 months ago

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

argenx SE Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 6 months ago

argenx SE Transcript: TD Cowen 46th Annual Health Care Conference

argenx SE Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

argenx SE Earnings Call Transcript: Q4 2025

argenx SE Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

argenx SE Annual report: Q4 2025

argenx SE Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

argenx SE Annual report: Q4 2025

argenx SE Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

argenx SE Earnings release: Q4 2025

argenx SE Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

argenx SE Slides: Q4 2025

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Feb 26, 2026, 1:00 AM EST - 6 months ago

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

Feb 26, 2026, 12:30 AM EST - 6 months ago

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

argenx to Present at TD Cowen 46th Annual Healthcare Conference

Feb 23, 2026, 1:00 AM EST - 6 months ago

argenx to Present at TD Cowen 46th Annual Healthcare Conference

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

Jan 13, 2026, 1:00 AM EST - 8 months ago

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

argenx SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 8 months ago

argenx SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

argenx SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 8 months ago

argenx SE Slides: 44th Annual J.P. Morgan Healthcare Conference

argenx Highlights 2026 Strategic Priorities

Jan 12, 2026, 1:00 AM EST - 8 months ago

argenx Highlights 2026 Strategic Priorities

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 1:00 AM EST - 8 months ago

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

argenx Announces Leadership Transition Marking Next Evolution of Growth

Jan 5, 2026, 1:00 AM EST - 8 months ago

argenx Announces Leadership Transition Marking Next Evolution of Growth

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 8 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN AZN IBB

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

Dec 15, 2025, 1:00 AM EST - 8 months ago

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 10 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

argenx SE Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 10 months ago

argenx SE Earnings Call Transcript: Q3 2025

argenx SE Earnings release: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 10 months ago

argenx SE Earnings release: Q3 2025

argenx SE Slides: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 10 months ago

argenx SE Slides: Q3 2025

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 2:00 AM EDT - 10 months ago

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

Oct 29, 2025, 11:00 AM EDT - 10 months ago

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

Oct 15, 2025, 1:00 AM EDT - 11 months ago

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Oct 3, 2025, 4:01 PM EDT - 11 months ago

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

Sep 18, 2025, 9:00 AM EDT - 11 months ago

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

argenx SE Transcript: Status Update

Sep 16, 2025, 2:00 PM EDT - 11 months ago

argenx SE Transcript: Status Update

argenx SE Slides: Status Update

Sep 16, 2025, 2:00 PM EDT - 11 months ago

argenx SE Slides: Status Update

argenx SE Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:00 AM EDT - 1 year ago

argenx SE Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

argenx SE Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 1 year ago

argenx SE Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 1 year ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

BBH BMRN CYTK IBB XBI

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Aug 25, 2025, 1:00 AM EDT - 1 year ago

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Aug 19, 2025, 1:00 AM EDT - 1 year ago

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Aug 12, 2025, 6:45 AM EDT - 1 year ago

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 1 year ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN AZN BAX BIIB

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 1 year ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN AZN BAX BIIB

argenx SE Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

argenx SE Earnings Call Transcript: Q2 2025

argenx SE Earnings release: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

argenx SE Earnings release: Q2 2025

argenx SE Slides: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

argenx SE Slides: Q2 2025

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Jul 31, 2025, 1:00 AM EDT - 1 year ago

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

howardlindzon
howardlindzon Sep. 2 at 6:32 PM
$ARGX yet another biotech at all time highs
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Sep. 2 at 6:31 PM
$ARGX printed a new 52-week high today
0 · Reply
moneybag888
moneybag888 Sep. 2 at 4:57 PM
$REGN new 52w HIGH $ARGX
0 · Reply
tradehulk
tradehulk Aug. 28 at 1:30 PM
$ARGX $LITE ⚡ BREAKING: Core AI Holdings delivers a stellar Q2 with revenue up 56%! 📊💰
0 · Reply
moneybag888
moneybag888 Aug. 27 at 11:11 PM
$ARGX 3 gaps down? or $1200+ to $1400+ #believe #befirst #alwayshedge
1 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 27 at 4:01 PM
$ARGX printed a new 52-week high today
0 · Reply
doubleyou2
doubleyou2 Aug. 27 at 1:49 PM
$ARGX Done.
0 · Reply
CDMO
CDMO Aug. 26 at 7:01 PM
$ARGX such a beast
1 · Reply
mv21970
mv21970 Aug. 26 at 5:01 PM
$BHVN cash runway extended through 2028 with first pivotal data for their degrader plattform expected late 2027 .. to get an idea what the company might be worth if BHV-1300 succeeds, look no further than where $ARGX is trading
1 · Reply
briefingcom
briefingcom Aug. 26 at 12:25 PM
$ARGX: argenx (+2.8%) upgraded to Buy from Neutral at UBS, tgt $1,400 https://www.briefing.com/calendars/updown?Filter=All&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
Mergerbrief
Mergerbrief Aug. 26 at 11:46 AM
$FBRX / $ARGX – Tender Offer Expires
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 24 at 8:01 PM
RECAP 8/24 +Pos Comments: $CIA + Freedom Broker RECAP 8/24 -Neg Comments: $XHLD - Fugazi Research $ARGX - DB $CRTO - Huber Research Live Breaking trading news www.openoutcrier.com
0 · Reply
moneybag888
moneybag888 Aug. 22 at 1:11 AM
$ARGX
0 · Reply
moneybag888
moneybag888 Aug. 21 at 7:07 PM
$REGN $PFE $ARGX $MRNA 😆
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 21 at 4:31 PM
$ARGX printed a new 52-week high today
0 · Reply
moneybag888
moneybag888 Aug. 21 at 3:46 PM
$REGN $1000+ join $ARGX $1000 club #befirst #believe
0 · Reply
moneybag888
moneybag888 Aug. 21 at 2:14 PM
$CORT #befirst $ARGX
0 · Reply
moneybag888
moneybag888 Aug. 21 at 2:10 PM
$ARGX
0 · Reply
moneybag888
moneybag888 Aug. 20 at 9:40 PM
$ARGX
0 · Reply
moneybag888
moneybag888 Aug. 20 at 9:19 PM
$ARGX
0 · Reply
WillieBaez283
WillieBaez283 Aug. 20 at 7:34 AM
$ARGX $MPWR $TRGP $CRH $TFC Argenx benefits from immunology drug demand and clinical expansion, Monolithic Power benefits from power-management and AI infrastructure demand, Targa Resources benefits from natural-gas and NGL volumes, CRH benefits from construction and infrastructure spending, and Truist benefits from banking activity. I'm watching prescription growth, AI power demand, energy throughput, construction spending, and credit quality.
0 · Reply
moneybag888
moneybag888 Aug. 20 at 6:06 AM
$ARGX 😆
0 · Reply